Disease · MONDO_0000328

hyperphosphatemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hyperphosphatemia. Diseases, record MONDO_0000328. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000328

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hyperphosphatemia; Open Targets
Open Targets ID: MONDO_0000328; Open Targets
Other names: Elevated phosphate ion concentration, Elevated phosphate ion level, Elevated phosphate ion level in blood, High blood phosphate levels, Increased phosphate ion concentration, Increased phosphate ion level, Increased phosphate ion level in blood, hyperphosphatemia (disease); Open Targets
Disease Ontology: DOID:0050459; Disease Ontology
MeSH: D054559; MeSH
Highest stage of its drugs: Approval, for 10 of its 21 drugs, from DailyMed, EMA Human Drugs and PMDA; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LANTHANUM CARBONATE	CHEMBL2096647	Small molecule	Approval	PMDA	17	16	16	Drugs and targets
SEVELAMER CARBONATE	CHEMBL5314347	Small molecule	Approval	EMA Human Drugs	12	10	10	Drugs and targets
BIXALOMER	CHEMBL4297202	Small molecule	Approval	PMDA	11	10	10	Drugs and targets
SEVELAMER HYDROCHLORIDE	CHEMBL1201492	Small molecule	Approval	EMA Human Drugs, at withdrawal	10	9	9	Drugs and targets
FERRIC CITRATE	CHEMBL3301597	Small molecule	Approval	DailyMed and EMA Human Drugs	11	8	7	Drugs and targets
FERRIC OXYHYDROXIDE	CHEMBL4802224	Small molecule	Approval	EMA Human Drugs and PMDA	10	8	8	Drugs and targets
COLESTILAN CHLORIDE	CHEMBL2103800	Small molecule	Approval	EMA Human Drugs, at withdrawal	7	6	6	Drugs and targets
CALCIUM ACETATE	CHEMBL1200800	Small molecule	Approval	DailyMed	14	4	4	Drugs and targets
SEVELAMER	CHEMBL5314349	Small molecule	Approval	EMA Human Drugs	5	4	4	Drugs and targets
TENAPANOR HYDROCHLORIDE	CHEMBL3301627	Small molecule	Approval	PMDA	2	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
SLC9A3	Sodium/hydrogen exchanger 3	2	Sodium/hydrogen exchanger 3 inhibitor	Approval	https://conductscience.org/library/genes/6550

Source Drugs and targets

Trials82

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03427125	A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis	Phase 3	1,559	2023-06-29	Hyperphosphatemia	TENAPANOR	Its record names the disease	ClinicalTrials.gov
NCT01464190	A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients	Phase 3	659	2014-02-17	Chronic Kidney Disease Requiring Chronic Dialysis	FERRIC OXYHYDROXIDE, SEVELAMER CARBONATE	Its record names the disease	ClinicalTrials.gov
NCT00542386	A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia	Phase 3	642	2014-10-06	Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Dyslipidemia	COLESTILAN CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00542815	A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia	Phase 3	632	2014-09-23	Chronic Kidney Disease, Dialysis, Hyperphosphatemia	COLESTILAN CHLORIDE, SEVELAMER	Its record names the disease	ClinicalTrials.gov
NCT00853242	Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis	Phase 2	349	2015-05-01	Kidney Failure, Chronic	SEVELAMER CARBONATE	Its record names the disease	ClinicalTrials.gov
NCT00416520	A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia	Phase 3	336	2014-10-23	Chronic Kidney Disease, Hyperphosphatemia	COLESTILAN CHLORIDE, SEVELAMER	Its record names the disease	ClinicalTrials.gov
NCT00506441	A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia	Phase 3	245	2014-07-25	Chronic Kidney Disease, Dialysis, Hyperphosphatemia	COLESTILAN CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03824587	Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy	Phase 2/3	236	2023-03-06	Hyperphosphatemia	TENAPANOR	Its record names the disease	ClinicalTrials.gov
NCT02675998	An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)	Phase 3	219	2020-08-10	Hyperphosphatemia	TENAPANOR	Its record names the disease	ClinicalTrials.gov
NCT01850602	A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia	Phase 3	213	2018-10-09	Hemodialysis, Hyperphosphatemia	FERRIC OXYHYDROXIDE, SEVELAMER HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 82

See all 82 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
PA21 vs Sevelamer Carbonate: serious adverse events	78 of 391	52 of 267	658	NCT01464190	Trial comparisons
Tenapanor 30 mg BID vs Placebo: deaths from any cause	0 of 117	0 of 119	236	NCT03824587	Trial comparisons
Tenapanor 30 mg BID vs Placebo: serious adverse events	3 of 117	5 of 119	236	NCT03824587	Trial comparisons
Tenapanor 30 mg BID vs Placebo: s-P Response at Week 4	43 of 116	26 of 119	235	NCT03824587	Trial comparisons
PA21 vs Sevelamer Hydrochloride: deaths from any cause	0 of 108	0 of 105	213	NCT01850602	Trial comparisons
PA21 vs Sevelamer Hydrochloride: serious adverse events	6 of 108	5 of 105	213	NCT01850602	Trial comparisons
Renvela vs Placebo: deaths from any cause	0 of 101	0 of 101	202	NCT03001011	Trial comparisons
Renvela vs Placebo: serious adverse events	26 of 101	31 of 101	202	NCT03001011	Trial comparisons
Calcium Acetate Oral Solution vs Sevelamer Carbonate: serious adverse events	2 of 38	1 of 38	76	NCT01427907	Trial comparisons
Ferric Citrate - Hemodialysis vs Ferric Citrate - Peritoneal Dialysis: deaths from any cause	0 of 27	0 of 27	54	NCT03079869	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials31

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25069799	RESULT	1	PubMed
24840781	RESULT	1	PubMed
24307220	RESULT	1	PubMed
21854503	RESULT	1	PubMed
18579668	RESULT	1	PubMed
18385391	RESULT	1	PubMed
42664364	DERIVED	3	PubMed
42387036	DERIVED	1	PubMed
41140700	DERIVED	1	PubMed
41033875	DERIVED	1	PubMed

1 to 10 of 31

See all 31 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000328

GET https://conductscience.org/api/diseases/v1/MONDO_0000328/drugs?page=2

API reference For AI assistants